G. Lockwood
Princess Margaret Cancer Centre
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by G. Lockwood.
European Urology | 2014
Alexandre R. Zlotta; Shin Egawa; Dmitry Pushkar; Alexander Govorov; Takahiro Kimura; Masahito Kido; Hiroyuki Takahashi; C. Kuk; Marta Kovylina; Najla Aldaoud; Neil Fleshner; Antonio Finelli; Laurence Klotz; G. Lockwood; Jenna Sykes; Theodorus van der Kwast
UNLABELLEDnInflammation has been suggested to be involved in the pathogenesis of benign prostatic hyperplasia (BPH). We studied the prevalence of inflammation and BPH in Asian and Caucasian men on prostate glands (n=320) obtained during autopsy in Moscow, Russia (Caucasian men, n=220), and Tokyo, Japan (Asian men, n=100). We correlated the presence and grade of acute inflammation (AI) or chronic inflammation (CI) and BPH. AI, CI, and histologic BPH were analyzed in a blinded fashion using a grading system (0-3). We used the Cochran-Armitage test for associations between the degree of BPH and clinical variables and proportional odds logistic regression models in multivariable analysis. Histologic BPH was observed in a similar proportion of Asian and Caucasian men (p=0.94). CI was found in>70% of men in both the Asian and Caucasian groups (p>0.05). Higher BPH scores were associated with more CI (p<0.001). In multivariate analyses, individuals with CI were 6.8 times more likely to have a higher BPH score than individuals without (p<0.0001). Men included in this study presented at the hospital and their symptomatic status was not known. The prevalence of CI and BPH on autopsy is similar in Asian and Caucasian men despite very different diet and lifestyle. CI is strongly associated in both groups with BPH.nnnPATIENT SUMMARYnIn this study, we looked at the prevalence of inflammation and benign prostatic hyperplasia (BPH) on autopsy in Asian and Caucasian men. We found chronic inflammation in>70% of men on autopsy. More chronic inflammation was associated with more BPH.
International Journal of Radiation Oncology Biology Physics | 2014
Jonathan Klein; Laura A. Dawson; Haiyan Jiang; John Kim; Rob Dinniwell; James D. Brierley; Rebecca Wong; G. Lockwood; Jolie Ringash
PURPOSEnTo evaluate quality of life (QoL), an important outcome owing to poor long-term survival, after stereotactic body radiation therapy (SBRT) to the liver.nnnMETHODS AND MATERIALSnPatients (n=222) with hepatocellular carcinoma (HCC), liver metastases, or intrahepatic cholangiocarcinoma and Child-Pugh A liver function received 24-60 Gy of 6-fraction image-guided SBRT. Prospective QoL assessment was completed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and/or Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep, version 4) questionnaires at baseline and 1, 3, 6, and 12 months after treatment. Ten HCC patients with Child-Pugh B liver function were also treated.nnnRESULTSnThe QLQ-C30 was available for 205 patients, and 196 completed the FACT-Hep. No difference in baseline QoL (P = .17) or overall survival (P = .088) was seen between the HCC, liver metastases, and intrahepatic cholangiocarcinoma patients. Appetite loss and fatigue measured by the QLQ-C30 clinically and statistically worsened by 1 month after treatment but recovered by 3 months. At 3 and 12 months after treatment, respectively, the FACT-Hep score had improved relative to baseline in 13%/19%, worsened in 36%/27%, and remained stable in 51%/54%. Using the QLQ-C30 Global Health score, QoL improved in 16%/23%, worsened in 34%/39%, and remained stable in 50%/38% at 3 and 12 months, respectively. Median survival was 17.0 months (95% confidence interval [CI] 12.3-19.8 months). Higher baseline scores on both FACT-Hep and QLQ-C30 Global Health were associated with improved survival. Hazard ratios for death, per 10-unit decrease in QoL, were 0.90 (95% CI 0.83-0.98; P = .001) and 0.88 (95% CI 0.82-0.95; P = .001), respectively. Tumor size was inversely correlated with survival.nnnCONCLUSIONSnLiver SBRT temporarily worsens appetite and fatigue, but not overall QoL. Stereotactic body radiation therapy is well tolerated and warrants comparison against other liver-directed therapies.
Practical radiation oncology | 2014
Barbara Wysocka; Joanne Moseley; Kristy K. Brock; G. Lockwood; Graham Wilson; Anna Simeonov; Masoom A. Haider; C. Menard; Jean-Pierre Bissonnette; Laura A. Dawson; Jolie Ringash
PURPOSEnTo characterize nonrespiratory stomach motion in the fasting state and postprandial.nnnMETHODS AND MATERIALSnTen healthy volunteers underwent 2-dimensional Fiesta cine magnetic resonance imaging studies in 30-second voluntary breath hold, in axial, coronal, and 2 oblique planes while fasting, and 5, 15, 30, 45, and 60 minutes postmeal. Each stomach contour was delineated and sampled with 200 points. Matching points were found for all contours in the same 30-second acquisition. Using deformable parametric analysis (Matlab, version 7.1), mean magnitude, and standard deviation of displacement of each point were determined for each patient. Maximal, minimal, and median population values in 6 cardinal, and in any direction, were calculated.nnnRESULTSnThe median of mean displacements for the baseline position of each point was small and rarely exceeded 1.1 mm; greatest value was 1.6 mm superior-inferior. Median displacement (pooled across time) in the right-left, superior-inferior, and anterior-posterior directions was 0.3 (range, -0.7 to 1.3), 0.8 (-0.4 to 2.4), and 0.3 (-1.1 to 1.6) mm, respectively. Fasting and postprandial standard deviation did not differ.nnnCONCLUSIONSnNonrespiratory stomach displacement is small and stomach position is stable after a small, standard meal. Radiation therapy may be delivered at any time within the first hour after eating without significant compromise of planned planning target volumes.
International Journal of Radiation Oncology Biology Physics | 2006
Jolie Ringash; B. Wysocka; Z. Kassam; G. Lockwood; Laura A. Dawson; James D. Brierley
European Urology Supplements | 2012
A.R. Zlotta; Shin Egawa; Dmitry Pushkar; Alexander Govorov; C. Kuk; Marta Kovylina; Najla Aldaoud; Neil Fleshner; A. Finelli; G. Lockwood; T.H. Van Der Kwast
International Journal of Radiation Oncology Biology Physics | 2005
Z. Kassam; James D. Brierley; Laura A. Dawson; G. Lockwood; G. Perkins; K. Churcher; Jolie Ringash
European Urology Supplements | 2014
A.R. Zlotta; Shin Egawa; Dmitry Pushkar; Alexander Govorov; Takahiro Kimura; Masahito Kido; Hiroyuki Takahashi; C. Kuk; Marta Kovylina; Najla Aldaoud; Neil Fleshner; A. Finelli; L. Klotz; G. Lockwood; Jenna Sykes; T.H. van der Kwast
International Journal of Radiation Oncology Biology Physics | 2008
Jolie Ringash; G. Lockwood; Mark Lee; Jun Oh Kim; R. Dinniwell; James D. Brierley; L.A. Dawson
International Journal of Radiation Oncology Biology Physics | 2007
Shao Hui Huang; G. Lockwood; J. Irish; Jolie Ringash; John Kim; John Waldron; Laura A. Dawson; A. Bayley; Bernard Cummings; Brian O'Sullivan
International Journal of Radiation Oncology Biology Physics | 2006
B. Wysocka; Z. Kassam; G. Lockwood; James D. Brierley; Laura A. Dawson; Jolie Ringash